{"url_path":"/sec/nbp/10-k/2026/item-19","section_key":"item-19","section_title":"Item 19 EXHIBITS","topic":"sec","document":{"doc_type":"20-F/A","doc_date":"2026-06-16","source_url":"https://www.sec.gov/Archives/edgar/data/1778016/0001778016-26-000006-index.html","accession_number":"0001778016-26-000006","cik":"0001778016","ticker":"NBP","issuer_name":"NovaBridge Biosciences","edgar_url":"https://www.sec.gov/Archives/edgar/data/1778016/0001778016-26-000006-index.html","primary_entity_key":"0001778016","primary_entity_name":"NovaBridge Biosciences"},"word_count":2385,"has_tables":true,"body_markdown":"## ITEM 19. EXHIBITS\n\nExhibit No.\n\nDescription of Exhibit\n\n1.1\n\n[Seventh Amended and Restated Memorandum and Articles of Association of the Registrant (incorporated herein by reference to Exhibit 3.1 to the current report on Form 6-K (File No. 333-234363), filed with the SEC on October 24, 2025)](https://www.sec.gov/Archives/edgar/data/1778016/000119312525250009/imab-ex3_1.htm)\n\n2.1\n\n[Registrant’s Specimen American Depositary Receipt (included in Exhibit 2.3)](https://www.sec.gov/Archives/edgar/data/1778016/000119312520193325/d75701dex43.htm)\n\n2.2\n\n[Registrant’s Specimen Certificate for Ordinary Shares (incorporated herein by reference to Exhibit 4.2 to the registration statement on Form F-1 (File No. 333-234363), as amended, initially filed with the SEC on October 29, 2019)](https://www.sec.gov/Archives/edgar/data/1778016/000119312520000969/d713200dex42.htm)\n\n2.3\n\n[Deposit Agreement dated as of January 22, 2020, among the Registrant the depositary and holder of the American Depositary Receipt (incorporated herein by reference to Exhibit 4.3 to the registration statement on Form S-8 (File No. 333-239871) filed with the SEC on July 15, 2020)](https://www.sec.gov/Archives/edgar/data/1778016/000119312520193325/d75701dex43.htm)\n\n2.4\n\n[Description of American Depositary Shares of the Registrant (incorporated herein by reference to Exhibit 2.5 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 29, 2020)](https://www.sec.gov/Archives/edgar/data/1778016/000119312520124785/d882254dex25.htm)\n\n2.5\n\n[Description of Ordinary Shares of the Registrant (incorporated herein by reference to Exhibit 2.6 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 29, 2020)](https://www.sec.gov/Archives/edgar/data/1778016/000119312520124785/d882254dex26.htm)\n\n3.1\n\n[Certificate of Incorporation on Change of Name (incorporated herein by reference to Exhibit 3.1 to the current report on Form 6-K (File No. 001-39173) furnished with the SEC on October 29, 2025)](https://www.sec.gov/Archives/edgar/data/1778016/000119312525256295/imab-ex3_1.htm)\n\n3\n\n \n\n \n\n \n\nExhibit No.\n\nDescription of Exhibit\n\n4.1\n\n[Second Amended and Restated 2017 Employee Stock Option Plan (incorporated herein by reference to Exhibit 10.1 to the registration statement on Form F-1 (File No. 333-234363), as amended, initially filed with the SEC on October 29, 2019)](https://www.sec.gov/Archives/edgar/data/1778016/000119312520000969/d713200dex101.htm)\n\n4.2\n\n[Second Amended and Restated 2018 Employee Stock Option Plan (incorporated herein by reference to Exhibit 10.2 to the registration statement on Form F-1 (File No. 333-234363), as amended, initially filed with the SEC on October 29, 2019)](https://www.sec.gov/Archives/edgar/data/1778016/000119312520000969/d713200dex102.htm)\n\n4.3\n\n[2019 Share Incentive Plan (incorporated herein by reference to Exhibit 10.22 to the registration statement on Form F-1 (File No. 333-234363), as amended, initially filed with the SEC on October 29, 2019)](https://www.sec.gov/Archives/edgar/data/1778016/000119312519277698/d713200dex1022.htm)\n\n4.4\n\n[2020 Share Incentive Plan (incorporated herein by reference to Exhibit 10.4 to the registration statement on Form S-8 (File No. 333-239871) filed with the SEC on July 15, 2020)](https://www.sec.gov/Archives/edgar/data/1778016/000119312520193325/d75701dex104.htm)\n\n4.5\n\n[2021 Share Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the registration statement on Form S-8 (File No. 333-256603) filed with the SEC on May 28, 2021)](https://www.sec.gov/Archives/edgar/data/1778016/000119312521176896/d572570dex101.htm)\n\n4.6\n\n[2022 Share Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the registration statement on Form S-8 (File No. 333-265684) filed with the SEC on June 17, 2022)](https://www.sec.gov/Archives/edgar/data/1778016/000110465922072363/tm2218782d1_ex10-1.htm)\n\n4.7\n\n[2024 Omnibus Incentive Plan (incorporated herein by reference to Exhibit 99.1 to the registration statement on Form S-8 (File No. 333-279842) filed with the SEC on May 30, 2024)](https://www.sec.gov/Archives/edgar/data/1778016/000110465924066741/tm2414081d1_ex99-1.htm)\n\n4.8\n\n[2025 Omnibus Share Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the registration statement on Form S-8 (File No. 333-290195) filed with the SEC on September 11, 2025)](https://www.sec.gov/Archives/edgar/data/1778016/000095017025114242/imab-ex10_1.htm)\n\n4.9\n\n[2025 Share Incentive Scheme (incorporated herein by reference to Exhibit 10.2 to the registration statement on Form S-8 (File No. 333-290195) filed with the SEC on September 11, 2025)](https://www.sec.gov/Archives/edgar/data/1778016/000095017025114242/imab-ex10_2.htm)\n\n4.10†\n\n[License and Collaboration Agreement, dated as of July 26, 2018, between the Registrant and ABL Bio (incorporated herein by reference to Exhibit 4.12 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 29, 2020)](https://www.sec.gov/Archives/edgar/data/1778016/000119312520124785/d882254dex412.htm)\n\n4.11\n\n[Amendment to Collaboration Agreement, dated as of November 5, 2018, between the Registrant and ABL Bio (incorporated herein by reference to Exhibit 4.15 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 3, 2025)](https://www.sec.gov/Archives/edgar/data/1778016/000095017025050344/imab-ex4_15.htm)\n\n4.12\n\n[Amendment Two to Collaboration Agreement, dated as of November 22, 2018, between the Registrant and ABL Bio](https://www.sec.gov/Archives/edgar/data/1778016/000095017025050344/imab-ex4_16.htm)[(incorporated herein by reference to Exhibit 4.16 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 3, 2025)](https://www.sec.gov/Archives/edgar/data/1778016/000095017025050344/imab-ex4_15.htm)\n\n4.13#\n\n \n\n[Amendment Three to Collaboration Agreement, dated as of May 24, 2019, between the Registrant and ABL Bio (incorporated herein by reference to Exhibit 4.17 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 3, 2025)](https://www.sec.gov/Archives/edgar/data/1778016/000095017025050344/imab-ex4_17.htm)\n\n4.14\n\n[Amendment Four to Collaboration Agreement, dated as of December 26, 2019, between the Registrant and ABL Bio (incorporated herein by reference to Exhibit 4.18 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 3, 2025)](https://www.sec.gov/Archives/edgar/data/1778016/000095017025050344/imab-ex4_18.htm)\n\n4.15\n\n[Amendment Five to Collaboration Agreement, dated as of June 30, 2020, between the Registrant and ABL Bio (incorporated herein by reference to Exhibit 4.19 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 3, 2025)](https://www.sec.gov/Archives/edgar/data/1778016/000095017025050344/imab-ex4_19.htm)\n\n4.16†\n\n[Amendment Six to Collaboration Agreement, dated as of September 24, 2021, between the Registrant and ABL Bio (incorporated herein by reference to Exhibit 4.20 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 3, 2025)](https://www.sec.gov/Archives/edgar/data/1778016/000095017025050344/imab-ex4_20.htm)\n\n4\n\n \n\n \n\n \n\nExhibit No.\n\nDescription of Exhibit\n\n4.17#\n\n[Amendment Seven to Collaboration Agreement, dated as of May 22, 2024, between the Registrant, ABL Bio and TJ Biopharma (Shanghai) Co., Ltd. (incorporated herein by reference to Exhibit 4.21 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 3, 2025)](https://www.sec.gov/Archives/edgar/data/1778016/000095017025050344/imab-ex4_21.htm)\n\n4.18*\n\n[Amendment Eight to Collaboration Agreement, dated as of November 2, 2025, between the Registrant and ABL Bio (incorporated herein by reference to Exhibit 4.18 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 7, 2026)](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/nbp-ex4_18.htm)\n\n4.19\n\n[Fourth Amended and Restated Shareholders Agreement, dated as of July 25, 2019 between the Registrant and other parties thereto (incorporated herein by reference to Exhibit 4.4 to the registration statement on Form F-1 (File No. 333-234363), as amended, initially filed with the SEC on October 29, 2019)](https://www.sec.gov/Archives/edgar/data/1778016/000119312519277698/d713200dex44.htm)\n\n4.20\n\n[Subscription Agreement, dated as of September 3, 2020, among the Registrant and certain affiliates of Hillhouse (incorporated herein by reference to Exhibit 2 of the Schedule 13D (File No. 005-91674) jointly filed by Hillhouse Capital Advisors, Ltd. and Hillhouse Capital Management, Ltd. with the SEC on September 14, 2020)](https://www.sec.gov/Archives/edgar/data/1762304/000090266420003304/exhibit_2.htm)\n\n4.21\n\n[Amendment to Subscription Agreement, dated as of December 17, 2020, among the Registrant and certain affiliates of Hillhouse (incorporated herein by reference to Exhibit 5 of the Schedule 13D/A (File No. 005-91674) jointly filed by Hillhouse Capital Advisors, Ltd. and Hillhouse Capital Management, Ltd. with the SEC on December 21, 2020)](https://www.sec.gov/Archives/edgar/data/1762304/000090266420004318/p20-2069exhibit5.htm)\n\n4.22\n\n[Form of Subscription Agreement, dated as of September 3, 2020, between the Registrant and certain investors (other than Hillhouse) (incorporated herein by reference to Exhibit 10.17 to the registration statement on Form F-1 (File No. 333- 251050), as amended, initially filed with the SEC on December 1, 2020)](https://www.sec.gov/Archives/edgar/data/1778016/000119312520307060/d98473dex1017.htm)\n\n4.23†\n\n[License and Collaboration Agreement, dated as of September 3, 2020, among I-Mab Shanghai, I-Mab U.S. and AbbVie Ireland Unlimited Company (incorporated herein by reference to Exhibit 10.19 to the registration statement on Form F-1 (File No. 333- 251050), as amended, initially filed with the SEC on December 1, 2020)](https://www.sec.gov/Archives/edgar/data/1778016/000119312520307060/d98473dex1019.htm)\n\n4.24†\n\n[Amendment No.1 to the License and Collaboration Agreement dated as of August 15, 2022 among I-Mab Shanghai, I-Mab U.S. and AbbVie Global Enterprise Ltd. (incorporated herein by reference to Exhibit 4.22 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on May 1, 2023)](https://www.sec.gov/Archives/edgar/data/1778016/000110465923053462/imab-20221231xex4d22.htm)\n\n4.25†\n\n[English translation of Shareholders Agreement, dated as of September 15, 2020, among I-Mab Biopharma (Hangzhou) Co., Ltd. and other parties thereto (incorporated herein by reference to Exhibit 10.21 to the registration statement on Form F-1 (File No. 333-251050), as amended, initially filed with the SEC on December 1, 2020)](https://www.sec.gov/Archives/edgar/data/1778016/000119312520307060/d98473dex1021.htm)\n\n4.26†\n\n[English translation of Equity Transfer Agreement of I-Mab Biopharma Co., Ltd., dated February 6, 2024, entered into by and among I-Mab Bio-tech (Tianjin) Co., Ltd., I-Mab Biopharma (Hangzhou) Co., Ltd. and I-Mab Biopharma Co., Ltd. (incorporated herein by reference to Exhibit 99.2 to the current report on Form 6-K (File No. 001-39173) furnished with the SEC on February 7, 2024)](https://www.sec.gov/Archives/edgar/data/1778016/000110465924011359/tm245234d1_ex99-2.htm)\n\n4.27\n\n[English translation of Equity Transfer Agreement of I-Mab Biopharma (Hangzhou) Co., Ltd., dated February 6, 2024, entered into by and among I-Mab Biopharma Hong Kong Limited, I-Mab Biopharma (Hangzhou) Co., Ltd. and the other parties thereto (incorporated herein by reference to Exhibit 99.3 to the current report on Form 6-K (File No. 001-39173) furnished with the SEC on February 7, 2024)](https://www.sec.gov/Archives/edgar/data/1778016/000110465924011359/tm245234d1_ex99-3.htm)\n\n4.28\n\n[English translation of I-Mab Biopharma (Hangzhou) Co., Ltd. Investment Agreement, dated February 6, 2024, entered into by and among I-Mab, I-Mab Biopharma Co., Ltd., I-Mab Biopharma (Hangzhou) Co., Ltd. and the other parties thereto (incorporated herein by reference to](https://www.sec.gov/Archives/edgar/data/1778016/000110465924011359/tm245234d1_ex99-4.htm)\n\n5\n\n \n\n \n\n \n\nExhibit No.\n\nDescription of Exhibit\n\n \n\n[Exhibit 99.4 to the current report on Form 6-K (File No. 001-39173) furnished with the SEC on February 7, 2024)](https://www.sec.gov/Archives/edgar/data/1778016/000110465924011359/tm245234d1_ex99-4.htm)\n\n4.29\n\n[English translation of I-Mab Biopharma (Hangzhou) Co., Ltd. Shareholders’ Agreement, dated February 6, 2024, entered into by and among I-Mab, I-Mab Biopharma Hong Kong Limited, I-Mab Biopharma (Hangzhou) Co., Ltd. and the other parties thereto (incorporated herein by reference to Exhibit 99.5 to the current report on Form 6-K (File No. 001-39173) furnished with the SEC on February 7, 2024)](https://www.sec.gov/Archives/edgar/data/1778016/000110465924011359/tm245234d1_ex99-5.htm)\n\n4.30†#\n\n[Clinical Trial Collaboration Agreement, dated as of June 5, 2024, among I-Mab US and Bristol-Myers Squibb Company (incorporated herein by reference to Exhibit 4.32 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 3, 2025)](https://www.sec.gov/Archives/edgar/data/1778016/000095017025050344/imab-ex4_32.htm)\n\n4.31\n\n[Assignment and Assumption Agreement, dated as of October 14, 2025, by and between Visara, Inc. and AffaMed Therapeutics (HK) Limited (incorporated by reference to exhibit 1.2 to the Current Report on Form 6-K/A (File No. 001-39173) furnished with the SEC on October 24, 2025)](https://www.sec.gov/Archives/edgar/data/1778016/000119312525249298/imab-ex1_2.htm)\n\n4.32\n\n[Exclusive License Agreement, dated November 6, 2021, by and between AskGene Pharma, Inc. and AffaMed Therapeutics (HK) Limited (incorporated by reference to exhibit 1.3 to the Current Report on Form 6-K/A (File No. 001-39173) furnished with the SEC on October 24, 2025)](https://www.sec.gov/Archives/edgar/data/1778016/000119312525249298/imab-ex1_3.htm)\n\n4.33\n\n[Exclusive License Agreement, dated as of October 15, 2025, by and between AskGene Pharma, Inc. and Visara, Inc. (incorporated by reference to exhibit 1.4 to the Current Report on Form 6-K/A (File No. 001-39173) furnished with the SEC on October 24, 2025)](https://www.sec.gov/Archives/edgar/data/1778016/000119312525249298/imab-ex1_4.htm)\n\n4.34*\n\n[Assignment and Assumption Agreement, dated October 28, 2025, by and between Visara, Inc., and Everest Medicines (incorporated herein by reference to Exhibit 4.34 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 7, 2026)](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/nbp-ex4_34.htm)\n\n4.35\n\n[Series A Preferred Stock Subscription Agreement, dated October 14, 2025 by and between Visara, Inc., I-Mab, and AffaMed Therapeutics (HK) Limited (incorporated by reference to exhibit 1.1 to the Current Report on Form 6-K/A ( File No. File No. 001-39173) furnished with the SEC on October 24, 2025)](https://www.sec.gov/Archives/edgar/data/1778016/000119312525249298/imab-ex1_1.htm)\n\n8.1*\n\n[Principal Subsidiaries of the Registrant (incorporated herein by reference to Exhibit 8.1 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 7, 2026)](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/nbp-ex8_1.htm)\n\n11.1\n\n[Code of Business Conduct and Ethics of the Registrant (incorporated herein by reference to Exhibit 11.1 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 3, 2025)](https://www.sec.gov/Archives/edgar/data/1778016/000095017025050344/imab-ex11_1.htm)\n\n11.2*\n\n[Insider Trading Policy of the Registrant (incorporated herein by reference to Exhibit 11.2 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 7, 2026)](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/nbp-ex11_2.htm)\n\n12.1**\n\n[Certification by Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](nbp-ex12_1.htm)\n\n12.2**\n\n[Certification by Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](nbp-ex12_2.htm)\n\n13.1*\n\n[Certification by Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (incorporated herein by reference to Exhibit 13.1 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 7, 2026)](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/nbp-ex13_1.htm)\n\n13.2*\n\n[Certification by Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (incorporated herein by reference to Exhibit 13.2 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 7, 2026)](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/nbp-ex13_2.htm)\n\n15.1*\n\n[Consent of JunHe LLP (incorporated herein by reference to Exhibit 15.1 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 7, 2026)](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/nbp-ex15_1.htm)\n\n6\n\n \n\n \n\n \n\nExhibit No.\n\nDescription of Exhibit\n\n15.2*\n\n[Consent of PricewaterhouseCoopers LLP (incorporated herein by reference to Exhibit 15.2 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 7, 2026)](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/nbp-ex15_2.htm)\n\n15.3*\n\n[Consent of PricewaterhouseCoopers Zhong Tian LLP (incorporated herein by reference to Exhibit 15.3 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 7, 2026)](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/nbp-ex15_3.htm)\n\n15.4*\n\n[Consent of Harney Westwood & Riegels (incorporated herein by reference to Exhibit 15.4 to the annual report on Form 20-F (File No. 001-39173) filed with the SEC on April 7, 2026)](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/nbp-ex15_4.htm)\n\n15.5\n\n[Letter from PricewaterhouseCoopers Zhong Tian LLP (incorporated herein by reference to Exhibit 99.2 to the current report on Form 6-K (File No. 001-39173) furnished with the SEC on August 7, 2024)](https://www.sec.gov/Archives/edgar/data/1778016/000110465924086547/tm2421036d1_ex99-2.htm)\n\n97.1\n\n[Clawback Policy of the Registrant (incorporated herein by reference to Exhibit 97.1 to the annual report on Form 20-F (File No. 001-39173) furnished with the SEC on April 30, 2024)](https://www.sec.gov/Archives/edgar/data/1778016/000110465924054452/imab-20231231xex97d1.htm)\n\n101.INS*\n\nInline XBRL Instance Document—this instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document\n\n101.SCH*\n\nXBRL Taxonomy Extension Schema Document\n\n101.CAL*\n\nXBRL Taxonomy Extension Calculation Linkbase Document\n\n101.DEF*\n\nXBRL Taxonomy Extension Definition Linkbase Document\n\n101.LAB*\n\nXBRL Taxonomy Extension Label Linkbase Document\n\n101.PRE*\n\nXBRL Taxonomy Extension Presentation Linkbase Document\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n## ___________\n\n* Previously filed\n\n** Filed herewith\n\n† Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.\n\n# Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the Securities and Exchange Commission.\n\n \n\n7\n\n \n\n \n\n \n\nSIGNATURES\n\n \n\nThe registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Amendment No. 1 to its annual report on its behalf.\n\nNovaBridge Biosciences\n\nBy: /s/ Kyler Lei______________________\n\nName: Kyler Lei\n\nTitle: Chief Financial Officer\n\nDate: June 16, 2026\n\n1"}